Repurposing of clinically developed drugs for treatment of Middle East respiratory syndrome coronavirus infection. - Test2 - elhamkhani - TriplyDB

Repurposing of clinically developed drugs for treatment of Middle East respiratory syndrome coronavirus infection.

Repurposing of clinically developed drugs for treatment of Middle East respiratory syndrome coronavirus infection.

http://www.wikidata.org/entity/Q30419612

about

Open drug discovery for the Zika virus Development of Medical Countermeasures to Middle East Respiratory Syndrome Coronavirus Middle East respiratory syndrome coronavirus: transmission, virology and therapeutic targeting to aid in outbreak control Anti-infective immunoadhesins from plants.Emergence of MERS-CoV in the Middle East: origins, transmission, treatment, and perspectives Middle East respiratory syndrome: obstacles and prospects for vaccine development The role of laboratory diagnostics in emerging viral infections: the example of the Middle East respiratory syndrome epidemic.A review of treatment modalities for Middle East Respiratory Syndrome.Abelson Kinase Inhibitors Are Potent Inhibitors of Severe Acute Respiratory Syndrome Coronavirus and Middle East Respiratory Syndrome Coronavirus Fusion.A screen of approved drugs and molecular probes identifies therapeutics with anti-Ebola virus activity.Ebola virus and severe acute respiratory syndrome coronavirus display late cell entry kinetics: evidence that transport to NPC1+ endolysosomes is a rate-defining step A Bibliometric Analysis of PubMed Literature on Middle East Respiratory Syndrome.Alternative screening approaches for discovery of Middle East respiratory syndrome coronavirus inhibitors.Treatment outcomes for patients with Middle Eastern Respiratory Syndrome Coronavirus (MERS CoV) infection at a coronavirus referral center in the Kingdom of Saudi Arabia.Screening of an FDA-approved compound library identifies four small-molecule inhibitors of Middle East respiratory syndrome coronavirus replication in cell culture.Coronaviruses resistant to a 3C-like protease inhibitor are attenuated for replication and pathogenesis, revealing a low genetic barrier but high fitness cost of resistance Middle East respiratory syndrome coronavirus: another zoonotic betacoronavirus causing SARS-like disease Development of human neutralizing monoclonal antibodies for prevention and therapy of MERS-CoV infections Infectious disease. Combating emerging viral threats.Pre- and postexposure efficacy of fully human antibodies against Spike protein in a novel humanized mouse model of MERS-CoV infection Inactivation and safety testing of Middle East Respiratory Syndrome Coronavirus.N-Desmethylclozapine, Fluoxetine, and Salmeterol Inhibit Postentry Stages of the Dengue Virus Life Cycle.A Universal Next-Generation Sequencing Protocol To Generate Noninfectious Barcoded cDNA Libraries from High-Containment RNA Viruses.Protective Effect of Intranasal Regimens Containing Peptidic Middle East Respiratory Syndrome Coronavirus Fusion Inhibitor Against MERS-CoV Infection Treatment strategies for Middle East respiratory syndrome coronavirus.Development of animal models against emerging coronaviruses: From SARS to MERS coronavirus Inhibition of Polyamine Biosynthesis Is a Broad-Spectrum Strategy against RNA Viruses.Immunogenicity of Candidate MERS-CoV DNA Vaccines Based on the Spike Protein.Computational modeling of the bat HKU4 coronavirus 3CL(pro) inhibitors as a tool for the development of antivirals against the emerging Middle East respiratory syndrome (MERS) coronavirus.Update in the treatment of non-influenza respiratory virus infection in solid organ transplant recipients.Human neutralizing antibodies against MERS coronavirus: implications for future immunotherapy FDA approved drugs as potential Ebola treatments.Update on therapeutic options for Middle East Respiratory Syndrome Coronavirus (MERS-CoV).Antiviral activity of cationic amphiphilic drugs.MERS-coronavirus: From discovery to intervention.Middle East respiratory syndrome coronavirus: five years later.A common feature pharmacophore for FDA-approved drugs inhibiting the Ebola virus.Infection with Middle East respiratory syndrome coronavirus.Treatment With Lopinavir/Ritonavir or Interferon-β1b Improves Outcome of MERS-CoV Infection in a Nonhuman Primate Model of Common Marmoset.Testing of Middle East respiratory syndrome coronavirus replication inhibitors for the ability to block viral entry.

P2860

Q22676298-B2294D86-96D8-4B31-B595-A20478C610FA Q26700054-C2E91B3A-7338-4EE3-8E54-577236BCCD36 Q26796501-56D736EB-0514-4699-907E-ADF302582448 Q26799080-A2238FFC-83CF-4638-B70E-87D5F7EBC329 Q26851859-7D892599-8BDA-4A8C-B776-D60E3699A9CA Q27013314-8B5B123F-E9E0-4840-9B49-DF98AF0F644D Q30235533-824F0F7A-09A6-42E4-94C2-E820B12C64ED Q30248209-80F82139-3F49-4CFB-88BB-3F5163A7CDA8 Q30276258-CD3C1628-3D88-4C34-91BC-7354F374AD94 Q30279239-52C60EC7-24B6-4424-B679-E9399311C927 Q30301030-55AF2219-4B48-49DE-972B-A3A6C20CE476 Q30389301-A8171CB3-DF82-4666-A95B-2721B8CF3A7F Q31161722-F9E2DF98-03BA-4C1E-873E-89B5FB47C69B Q33431629-0F6D7393-B925-4A77-9D3C-3B3CBB0D57E7 Q34058365-F96387FF-F788-402C-B577-BFC545F8F549 Q34261616-3D9F7255-BD52-462B-9CCD-6B3704316AAC Q34468689-DA51283B-508F-44AC-BD3C-74D3B8250922 Q35019893-2D2679D5-6629-4B57-BAD6-9D9B261AF8E6 Q35569547-343B778E-0F44-46E0-B08F-FEC6DAA6AA71 Q35865538-6A49AFA1-9FE9-4E98-BF5C-31DFF5948E5B Q36012570-34F7AA14-FBAE-4ED1-BC9F-54061024B9DC Q36116232-8AB989A5-0CFE-4458-BC8B-9BAE2105E715 Q36185161-696AF9F4-DB4C-4D68-A79F-45CA3D7116D2 Q36306931-62A805A3-BC97-4DEF-B200-D950D0AE52C4 Q36555622-CDAC96EC-AC9B-4853-BD2A-D7ECF0B377BE Q36691163-B2CC497B-6150-455A-AE74-E5B8164120E0 Q37347305-C76E4D3F-EC3B-4302-A83C-6FD94136DB3A Q37717377-93E4B810-EE2B-4CEE-A898-E6EF22F2E553 Q38728233-EE897DE4-EFFA-4AA7-9609-7915FD144F84 Q38829076-CAB44074-DAD4-44FC-8727-753C7002979B Q38993000-DD7B7E8F-6C06-4A33-BD6F-BC4D35CD81D5 Q39027505-1872D458-EE7C-45F8-91F4-48DAE8C98BA3 Q39034541-656E2502-C4A9-4318-BEF5-B0DA2F735EFF Q39175768-801E044C-911C-4F37-A335-2D9BC3FAE268 Q39374922-70DD774A-793C-47E8-BC38-F107B308083A Q40085786-369B8244-FDFF-402C-9CE3-07EBC3859341 Q40170777-72E0C1C6-66F8-4F83-90A2-9217B32041A6 Q40910573-FB91CB45-FB4B-4949-82E6-BE2D4E045981 Q41096904-A42094BC-B99A-45AD-9D34-2B974C196C2A Q42786664-32D4FAFC-1A5A-40BA-B3FE-3A7FD31E3C97

P2860

Repurposing of clinically developed drugs for treatment of Middle East respiratory syndrome coronavirus infection.

http://www.wikidata.org/entity/Q30419612

description

2014 nî lūn-bûn

@nan

2014 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Repurposing of clinically deve ...... yndrome coronavirus infection.

@ast

Repurposing of clinically deve ...... yndrome coronavirus infection.

@en

type

label

Repurposing of clinically deve ...... yndrome coronavirus infection.

@ast

Repurposing of clinically deve ...... yndrome coronavirus infection.

@en

prefLabel

Repurposing of clinically deve ...... yndrome coronavirus infection.

@ast

Repurposing of clinically deve ...... yndrome coronavirus infection.

@en

P1433

Q30419612-DEB5D8AE-A277-4184-9160-80E7BD00D35F

P1476

Q30419612-A6E821D1-BCC4-4BBF-BB7C-B57BB9ACA1D8

P2093

Q30419612-04E17468-5882-4F51-B922-267EB2C41DF9

Q30419612-9D1CFA22-CF57-46C3-B1CD-AED702AB7F96

Q30419612-A20890CE-EAF3-4958-AEA0-9357DF129F5B

Q30419612-D21DC8CB-8A5D-421A-9D81-306A52BBFF3C

Q30419612-E237BE57-BC53-47BF-8731-85ABF60906F9

Q30419612-F71ECB61-4037-4A71-86CA-86AE5CE1771B

Q30419612-FC3C2FD6-D076-4D83-9B5A-71105556F1A1

Q30419612-FDF2720D-651D-4C79-BB6F-249295E14FB9

P2860

Q30419612-00A4D9BB-5FCD-4208-8D6E-6EFEBE9AEC28

Q30419612-0DD40A11-74C4-4866-92ED-69AD10DBDB37

Q30419612-127AE7BF-EA17-4262-9284-01B126F13B03

Q30419612-1E073BA7-737B-4A87-8B03-BD5D0D3B8589

Q30419612-2162C83D-E73F-4808-89D5-776D094F4C4D

Q30419612-229673EB-20C7-4E56-B3C3-64AC3A0FE7BB

Q30419612-29D943C0-2627-4A4A-8358-91864ECAB876

Q30419612-2D1D1EF7-514D-4296-B089-415365F07080

Q30419612-3969FC5E-BB34-4775-8AC3-3BAF4EFBAEAD

Q30419612-3EEC1B6A-706C-45AE-937F-5577567E3E3A

P304

Q30419612-F93124AA-9451-46E9-AEAD-7BDCE61F4F3B

P31

Q30419612-358F5912-7184-4EDB-B7B6-E5E9E3C08762

P356

Q30419612-93678734-DB8B-4C45-98BB-5DA1591D9C7F

P407

Q30419612-702687D0-5D64-4417-BF63-019F7C0F6317

P433

Q30419612-8AA1D483-5A08-479B-8691-646480B89EF9

P478

Q30419612-5D1307F0-89E8-4BDD-93BD-4F40E1053810

P50

Q30419612-74A74E98-2EAE-4F79-BC7E-3C92228DFB27

Q30419612-78C21EB5-14A6-4BE3-8516-926CED816E5A

Q30419612-8AABA711-EA8B-4BD5-B925-FD0FE997B3C0

Q30419612-8D55901C-6E44-488A-96D4-C16C14409506

Q30419612-A7E6E0BC-764F-44ED-AD72-8AD92A45C1B5

Q30419612-CE434A08-A0DE-4DE5-900A-5AC1B9CEB807

Q30419612-EEEC92B7-D91E-4E1D-8B05-9BF584E80770

Q30419612-FDB08447-84F1-46E9-B1B3-3FFAC3E15653

P577

Q30419612-25F06C07-5DFD-4D50-BD2F-03F8894DE20C

P698

Q30419612-E698A76D-548A-4FD9-9412-0411C6823CDD

P921

Q30419612-5846D1C1-F213-4B9A-8938-6CC54D175239

Q30419612-FD5AE066-E383-4AF0-9FC5-15B16F7F88A2

P932

Q30419612-010273A4-21FC-471D-B1AF-5032B8B7408E

P356

P1433

Antimicrobial Agents and Chemotherapy

P1476

Repurposing of clinically deve ...... yndrome coronavirus infection.

@en

P2093

Calli M Lear-Rooney

http://www.w3.org/2001/XMLSchema#string

Julie Dyall

http://www.w3.org/2001/XMLSchema#string

Lisa M Johansen

http://www.w3.org/2001/XMLSchema#string

Matthew B Frieman

http://www.w3.org/2001/XMLSchema#string

Michael R Holbrook

http://www.w3.org/2001/XMLSchema#string

Monique Laidlaw

http://www.w3.org/2001/XMLSchema#string

Pamela J Glass

http://www.w3.org/2001/XMLSchema#string

Reed F Johnson

http://www.w3.org/2001/XMLSchema#string

P2860

State of Knowledge and Data Gaps of Middle East Respiratory Syndrome Coronavirus (MERS-CoV) in Humans

A systematic screen of FDA-approved drugs for inhibitors of biological threat agents

Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC

FDA-approved selective estrogen receptor modulators inhibit Ebola virus infection.

Middle East respiratory syndrome coronavirus in bats, Saudi Arabia

Middle East respiratory syndrome coronavirus (MERS-CoV): announcement of the Coronavirus Study Group

Towards evidence based emergency medicine: best BETs from the Manchester Royal Infirmary. Chlorpromazine in migraine

Identification of selective inhibitors of cancer stem cells by high-throughput screening

Multiple cationic amphiphiles induce a Niemann-Pick C phenotype and inhibit Ebola virus entry and infection

Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia

P304

4885-4893

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/AAC.03036-14

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

58

http://www.w3.org/2001/XMLSchema#string

P50

Peter B. Jahrling

Jason Kindrachuk

Christopher Coleman

Thiagarajan Venkataraman

P577

2014-05-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24841273

http://www.w3.org/2001/XMLSchema#string

P921

Middle East respiratory syndrome coronavirus

P932

4136000

http://www.w3.org/2001/XMLSchema#string